Naloxegol: A review of its use in patients with opioid-induced constipation

Drugs

Volumn 75, Issue 4, 2015, Pages 419-425

  Garnock Jones, Karly P ^a  

^a Springer ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

NALOXEGOL; MACROGOL DERIVATIVE; MORPHINAN DERIVATIVE; MU OPIATE RECEPTOR; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ABDOMINAL PAIN; ANXIETY; AREA UNDER THE CURVE; ARTICLE; CHILL; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; HUMAN; HYPERHIDROSIS; IN VITRO STUDY; IRRITABILITY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OPIOID INDUCED CONSTIPATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); UPPER ABDOMINAL PAIN; VOLUME OF DISTRIBUTION; VOMITING; YAWNING; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; METABOLISM; PROCEDURES;

ANALGESICS, OPIOID; CONSTIPATION; HUMANS; MORPHINANS; NARCOTIC ANTAGONISTS; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, OPIOID, MU;

EID: 84925539077     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0357-2     Document Type: Article

References (20)

1. Brock C, Olesen S, Olesen A, et al. Opioid-Induced Bowel Dysfunction. Drugs. 2012;72(14):1847-65.
2. Camilleri M, Drossman DA, Becker G, et al. Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. Neurogastroenterol Motil. 2014;26:1386-95.
3. AstraZeneca. Movantik™ (naloxegol tablets): US prescribing information. 2014. http://www.astrazeneca-us.com/cgi-bin/az-pi.cgi?product=movantik&country=us&popup=no. Accessed 23 Jan 2015.
4. European Medicines Agency. Moventig® (naloxegol oxalate tablets): EU summary of product characterisitics. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002810/WC500179075.pdf. Accessed 23 Jan 2015.
5. AstraZeneca. Naloxegol (NDA 204-760) Briefing Document for the Anesthetic and Analgesic Drug Products Advisory Committee. 2014. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anestheticandanalgesicdrugproductsadvisorycommittee/ucm400209.pdf. Accessed 27 Nov 2014.
6. Eldon M, Song D, Neumann TA, et al. NKTR-118 (oral PEG-naloxol), a PEGylated derivative of naloxone: demonstration of selective peripheral opioid antagonism after oral administration in preclinical models [abstract no. 28 plus poster]. In: 18th annual clinical meeting of the American Academy of Pain Management. 2007.
7. Neumann TA, et al. Evaluation of PEG-Naloxol (NKTR-118) as an oral peripheral Opioid Antagonist in healthy male subjects: a double-blind, placebo-controlled, dose escalation crossover study [abstract no. II-36]. In: 36th annual meeting of the American College of Clinical Pharmacology. 2007.
8. Odinecs A, Gadiraju R, Sisco J, et al. Comparative bioavailability of NKTR-118 tablets and solution: a case of bioequivalence between dosage forms for a rapidly absorbed drug [abstract no. 140]. J Clin Pharmacol. 2009;49(9):1123.
9. Gottfridsson C, Carlson G, Lappalainen J, et al. Evaluation of the effect of naloxegol on cardiac repolarization: a randomized, placebo- and positive-controlled crossover thorough QT/QTc study in healthy volunteers. Clin Ther. 2013;35(12):1876-83.
10. Bui KH, Hutchison M, Brunnstrom A, et al. Absorption, Metabolism and Excretion of [14C]-Naloxegol in Human Subjects [abstract no. R6319 plus poster]. In: American Association of Pharmaceutical Scientists Annual Meeting and Exposition. 2013.
11. Sahner D, van Paaschen H, et al. Results from a phase I, double-blind, randomized, placebo-controlled, multiple-dose study evaluating the safety, tolerability, and pharmacokinetics of oral doses of NKTR-118 [abstract no. 210 plus poster]. J Pain. 2008;9(4 Suppl 2):P28.
12. Bui K, She F, Sostek M. The effects of mild or moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of naloxegol. J Clin Pharmacol. 2014. doi: 10.1002/jcph.348.
13. Bui K, She F, Sostek M. The effects of renal impairment on the pharmacokinetics, safety, and tolerability of naloxegol. J Clin Pharmacol. 2014;. doi: 10.1002/jcph.349.
14. Bui K, Zhou D, Sostek M, et al. Effects of CYP3A modulators on the PK of naloxegol [abstract no. PI-108]. Clin Pharmacol Ther. 2014;95(Suppl. 1):S53.
15. Bui KH, She F, Zhou D, et al. Evaluation of the effect of quinidine, a strong Pgp inhibitor, on the pharmacokinetics and CNS distribution of naloxegol [abstract no. 1710175]. Clin Pharmacol Drug Dev. 2013;2(Suppl. 1):8-9.
16. Webster L, Dhar S, Eldon M, et al. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. Pain. 2013;154(9):1542-50.
17. Chey WD, Webster L, Sostek M, et al. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370(25):2387-96.
18. Chey W, Tack J, Webster L, et al. Efficacy of naloxegol in a subpopulation of patients with opioid-induced constipation and an inadequate baseline response to laxatives: results from two, prospective, randomized controlled trials [abstract no. 1884]. Am J Gastroenterol. 2013;108(Suppl. 1):S570.
19. Webster L, Chey WD, Tack J, et al. Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation. Aliment Pharmacol Ther. 2014;40(7):771-9.
20. Von Roenn JH, Tack J, Barker PN, et al. Challenges in patient recruitment during KODIAC-06, a randomized, placebo-controlled, double-blind, multicenter, phase 3 trial of naloxegol in patients with neoplasia and opioid-induced constipation (OIC). Support Care Cancer. 2013;21:S259.